LEVERAGING PROGRESS, SEIZING OPPORTUNITIES

CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS

OCTOBER 13-14, 2016 • GENEVA, SWITZERLAND
Dear Colleagues:

Welcome to the fifth annual Controlling the HIV Epidemic with Antiretrovirals summit, organized by the International Association of Providers of AIDS Care (IAPAC) in partnership with the Joint United Nations Programme on HIV/AIDS (UNAIDS) and other partners. We are here these two days to explore the ways in which we will improve population health in heavily HIV affected regions within the next five years, setting the stage for ending AIDS as a public health threat by 2030.

The rationale for this annual summit is more compelling than ever, given the culmination of several important studies this past year. The START and TEMPRANO studies convincingly demonstrated that the initiation of antiretroviral (ART) as soon as patients are diagnosed with HIV and understanding the importance of daily adherence results in decreased HIV morbidity and mortality. Moreover, the data from START and TEMPRANO offer hope that early ART initiation can significantly decrease the global tuberculosis (TB) syndemic.

Additionally, with the final report from HPTN 052, we now definitively know that early ART initiation is among the most effective HIV prevention interventions, reducing transmission by more than 90% after close to 10,000 person years of follow-up. The Partner study’s final report published earlier this year in the Journal of the American Medical Association also documented zero HIV transmissions after condomless vaginal or anal sex when the HIV-positive partner was virologically suppressed. The beneficial findings associated with early ART are also complemented by additional reports that the use of pre-exposure prophylaxis (PrEP) can effectively decrease HIV acquisition among high-risk populations. A pragmatic study, PROUD, conducted in British genitourinary medicine clinics, demonstrated that the integration of PrEP within the context of sexual health in primary care settings can be highly effective, approaching 90% protection in a very real-world setting.

The challenge for our discussions this year in Geneva is to how to best translate these exciting research findings into public health policy that leaves no one behind. We have the tools to turn the tide on this persistent global pandemic, and the modelling indicates that we can do so by 2020 if we attain the UNAIDS 90-90-90 and zero stigma and discrimination targets, as well as scale up all other HIV prevention interventions, including PrEP. The question is whether we will leverage the progress that we have made to date, avoid the risks that come with entrenched complacency and divergent agendas, and seize the opportunities before us to control the HIV epidemic.

Ultimately, our goal to end AIDS as a public health threat by 2030 is only possible through a combination of commitment, innovation, partnership, and action – which are the mainstay of this annual series of IAPAC summits. We hope that the scheduled plenaries and panel discussions as well as formal and informal discussions throughout the next two days will provide you with new insights and new contacts to facilitate further optimization of the use of antiretrovirals to control the HIV epidemic.

Best wishes for a productive summit,

Kenneth H. Mayer, MD
Co-Chair

Paula Munderi, MD
Co-Chair

Julio S.G. Montaner, MD
Honorary Co-Chair

1 Fenway Institute, Boston, MA, USA
2 Medical Research Council, Kampala, Uganda
3 British Columbia Centre of Excellence in HIV/AIDS, Vancouver, BC, Canada
Dear Colleagues,

Welcome to the 2016 Controlling the HIV Epidemic with Antiretrovirals summit.

The International Association of Providers of AIDS Care (IAPAC) is honored to co-host this year’s summit with the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Foundation for AIDS Research (amfAR), the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS), and the Geneva University Hospitals.

On behalf of IAPAC, I recognize the contributions made by those of you who are joining us here in Geneva from 55 countries, among you:

• Representatives from advocacy groups and healthcare provider associations, including Human Rights Watch, IAPAC, the European AIDS Clinicians Society, and the International AIDS Society;
• UNAIDS, the United Nations Children’s Fund, and the World Health Organization;
• The US President’s Emergency Plan for AIDS Relief; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and UNITAID, as well as private sector donors, including amfAR, the Elton John AIDS Foundation, Gilead Sciences, Merck & Co., and ViiV Healthcare;
• Research institutions such as the ANRS and the US National Institutes of Health, and government and non-governmental implementing agencies such as EGPAF, FHI360, Médecins sans Frontières, the US Centers for Disease Control and Prevention, and the US Agency for International Development;
• Federal and state health ministries from 27 countries, and representatives from 14 Fast-Track Cities – Amsterdam, Bangkok, Dakar, Dar es Salaam, Denver, Geneva, Kyiv, Lagos, Lilongwe, Melbourne, Mexico City, New York City, Windhoek, and Yaoundé; and
• Individuals who share in our mutual concern that we are not moving fast enough to avert many more AIDS-related deaths and new HIV infections.

We have achieved much together over the past 35 years of the global HIV pandemic. With the dawn of antiretroviral therapy (ART) in the mid-1990s, we ushered in a new era in which an HIV diagnosis was no longer an automatic death sentence. The results of HTPN 052 a few short years ago confirmed that ART is life-saving/-enhancing and a biomedical HIV prevention intervention. Today more than 17 million people living with HIV are on ART and benefiting from its therapeutic and preventative effects.

These very successes have added layers of complexity to our efforts that deserve critical reflection, particularly as we strive to end AIDS as a public health threat. We must ask ourselves: Are we merely maintaining the structures of the status quo and perpetuating divergent agendas that will delay progress toward HIV control, elimination, and eradication? Or are our actions truly being carried forward in the best interest of those communities that stand to benefit, particularly key affected populations?
The course of action that we assume from this moment forward will speak to the spirit that resides within and drives our global HIV community. The critical juncture at which we find ourselves is defined by the progress that I have referenced as well as the unprecedented opportunities that we now have to control the HIV pandemic. The emphasis must be on cooperation to ensure that no man, woman, or child is left behind as we strive to attain the United Nations’ 90-90-90 targets in a rights-based approach that is predicated on the ability for each of us to realize the human right to health.

Whether we, as leaders in the global HIV movement, coalesce around the tools at our disposal and lean forward to attain the 90-90-90 targets will be the most immediate test of our commitment and resolve. Data signal an opportunity to leverage ART to prevent illness, death, and transmission and thus control the HIV epidemic. Important adjuncts to our primary goal of reaching and saving the lives of 20 million people not currently on ART include the means by which to curb HIV acquisition, including condoms, pre-exposure prophylaxis (PrEP), harm reduction, and other prevention interventions.

The “business as usual” approach to our global AIDS response has been shattered. Yet, much work remains to cross geographic and philosophical borders; forge innovative, logical, and meaningful partnerships; and comport ourselves with concern for those in whose service we labor. Our work also must be on a scale and at a pace that allows us to rapidly avert AIDS-related deaths (more than 2,000 children and 19,200 adults are dying weekly), as well as prevent new HIV infections (more than 2,800 babies and 37,000 adults are newly infected daily).

In advancing a non-business as usual approach, let us also remain ever cognizant that every action we advance along what I refer to as a “continuum to zero” – zero new HIV infections and zero AIDS-related deaths – must be taken out of concern for the dignity which HIV all too often strips from individuals, communities, and nations. We must conscientiously suffuse our efforts with the premise of dignity and human rights, including the right to HIV treatment. In so doing, we will be rewarded in our time by knowing that we have contributed to the preservation and renaissance of communities and nations.

I wish you a productive two days of meaningful and robust discussions regarding our way forward.

Warmest regards,

José M. Zuniga
IAPAC President/CEO
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speakers/Panelists</th>
</tr>
</thead>
</table>
| 0900-0930 | OPENING REMARKS                                                                                     | Are We at the End of the Beginning or the Beginning of the End of Our Efforts to Control the HIV Epidemic?  
José M. Zuniga  
Julio S.G. Montaner  
Kenneth H. Mayer  
Paula Munderi |  
| 0930-1000 | KEYNOTE ADDRESS                                                                                     | Strategies, Emerging Opportunities, and Political Processes to Reach 90-90-90  
Michel Sidibé |  
| 1000-1100 | HIGH-LEVEL PANEL DISCUSSION                                                                         | Perspectives on 90-90-90 and Zero Discrimination and Stigma within the Context of the Sustainable Development Goals  
Moderator: Amb. Lennarth Hjelmåker  
Panelists:  
Amb. Deborah L. Birx  
Lucia Ditiu  
Mark R. Dybul  
Lelio Marmora  
Michel Sidibé |  
| 1100-1130 | COFFEE BREAK                                                                                         |  
| 1130-1200 | JONATHAN MANN MEMORIAL LECTURE                                                                      | Prioritizing AIDS in a World “Fatigued” by HIV: A Human Rights and Economics Argument for Finishing What We Started  
Jeffrey Sachs |  
| 1200-1230 | SPECIAL PRESENTATION PANEL                                                                           | Task-Shifting for 90-90-90: Strategically Deploying Human Resources for Health  
Moderators:  
Anja Giphart  
Badara Samb  
Panelists:  
Michel Sidibé  
Jeffrey Sachs  
José M. Zuniga  
Mark Heywood  
James Campbell |  
| 1230-1400 | LUNCH PANEL DISCUSSION                                                                               | The Role of Innovation to End AIDS as a Public Health Threat by 2030  
Moderators:  
Francesca Celletti  
José M. Zuniga  
Panelists:  
Isabelle Andrieux-Meyer  
Jennifer Cohn  
Reuben Granich  
Francois Venter  
Mikkel Vestergaard Frandsen |  
| 1400-1430 | JOEP MA LANGE MEMORIAL LECTURE                                                                        | Avoiding the Cost of Invisibility: Leaving No One Behind as We Attain 90-90-90  
Amb. Deborah L. Birx |  
| 1430-1530 | PANEL DISCUSSION                                                                                      | Challenges and Opportunities to Optimizing the HIV Care Continuum – Can We Test and Treat Enough People to Make a Seismic Difference by 2030?  
Moderators:  
Alexandra Calmy  
Jean-François Delfraissy  
Presenter: Reuben Granich  
Discussants:  
Terri Ford  
Sharonann Lynch  
James McIntyre  
John Pottage  
Brian Williams |  
| 1530-1600 | COFFEE BREAK                                                                                         |  

Controlling the HIV Epidemic with Antiretrovirals - 13-14 October 2016
HIV TREATMENT FOR ALL

1600-1700  PANEL DISCUSSION
Leadership in Action: Case Studies in Implementing HIV Treatment for All
Moderators:
Mandeep Dhaliwal
Sarah Rowan
Presenter: Gottfried Hirnschall
Discussants:
Florentino Badial-Hernández
Joshua Kimani
Sabin Nsanzimana
Praphan Phanuphak
Francois Venter

1700-1800  PANEL DISCUSSION
Focusing the Clinical Response: Can Differentiated Care Accelerate the Implementation of HIV Treatment for All?
Moderators:
Meg Doherty
Paula Munderi
Presenter: Eric Goemaere
Discussants:
Francesca Celletti
Kevin de Cock
Lucica Ditui
Benjamin Young
Anna Zakowicz

1800  ADJOURN

1800-2000  IAPAC 30th ANNIVERSARY COMMEMORATION AND RECEPTION
# FRIDAY 14 OCTOBER 2016

## OPTIMIZING THE HIV PREVENTION CONTINUUM

### 0900-0930  
**PLENARY ADDRESS**  
State-of-the-Science – When HIV Treatment is Prevention, What Then Do We Mean by “Prevention”?  
**Catherine Hankins**  
**Kenneth H. Mayer**

### 0930-1030  
**PANEL DISCUSSION**  
Challenges to and Opportunities for PrEP Uptake: What Have We Learned? What Gaps Must We Fill?  
**Moderators:**  
Jane Anderson  
Kenneth H. Mayer  
**Discussants:**  
K. Rivet Amico  
Marcelo Araújo de Freitas  
Michael Cassell  
Catherine Hankins  
Bruno Spire

### 1030-1100  
**COFFEE BREAK**

### 1100-1200  
**PANEL DISCUSSION**  
Leadership in Action: Case Studies in Implementing PrEP within the Context of Combination HIV Prevention  
**Moderators:**  
Rachel Baggaley  
Nikos Dedes  
**Panelists:**  
Náatia Cerqueira  
Demetre Daskalakis  
Josephine Odoyo  
Maria Prins  
Kevin Rebe

### 1200-1300  
**PANEL DISCUSSION**  
Gearing Up for PrEP 2.0 – Can Scientific and Other Innovations Transform PrEP into a More Powerful Game Changer across Key Populations?  
**Moderators:**  
Manuel Battegay  
Celso Ramos  
**Presenter:** Karen Hoover  
**Discussants:**  
Rachel Baggaley  
David Haerry  
Tetiana Kiriazova  
Patrick Oyaro  
Midnight Poohnaksetwattana  
James Rooney

### 1300-1430  
**LUNCH PANEL DISCUSSION**  
Pulling in One Direction: Integrating the HIV Treatment and Prevention Agenda with the Cure and Vaccine Cure Agendas  
**Moderators:**  
Araja Giphart  
Luiz Loures  
**Panelists:**  
Noel Gill  
Rolando Barrios  
Asier Sáez-Cirión

## LEAVING NO ONE BEHIND

### 1430-1530  
**PANEL DISCUSSION**  
Situation Report on our Quest to End AIDS as a Public Health Threat by 2030  
**Moderators:**  
Gregorio Millett  
Bernard Hirschel  
**Presenter:** Mariângela Simão  
**Discussants:**  
Bertrand Audoin  
Esteban Burrone  
Andreas Jahn  
Chewe Luo  
Jorge Saavedra

### 1530-1600  
**COFFEE BREAK**

### 1600-1700  
**CLOSING PANEL DISCUSSION**  
Delivering on the Promise of an AIDS-Free Generation: Defining The Way Forward to Attain 90-90-90 and Zero Stigma and Discrimination Targets by 2020  
**Moderator:** Mitchell Besser  
**Panelists:**  
Mirriam Lethlokoa  
Luiz Loures  
Paula Munderi  
Kenly Sikwese  
José M. Zuniga

### 1700  
**ADJOURN**
K. Rivet Amico
University of Michigan
Ann Arbor, MI, USA

Jane Anderson
Homerton University Hospital
London, England

Isabelle Andrieux-Meyer
Médecins sans Frontières
Geneva, Switzerland

Marcelo Araújo de Freitas
Ministry of Health
Brasilia, Brazil

Bertrand Audoin
International Association of Providers of AIDS Care
Geneva, Switzerland

Florentino Badial-Hernández
Clinica Condesa
Mexico City, Mexico

Rachel Baggaley
World Health Organization
Geneva, Switzerland

Manuel Battegay
University of Basel
Basel, Switzerland

Mitchell Besser
Mothers2Mothers
Cape Town, South Africa

Amb. Deborah L. Birx
Office of the Global AIDS Coordinator
Washington, DC, USA

Esteban Burrone
Medicines Patent Pool
Geneva, Switzerland

Alexandra Calmy
Geneva University Hospitals
Geneva, Switzerland

James Campbell
World Health Organization
Geneva, Switzerland

Michael Cassell
United States Agency for International Development
Washington, DC, USA

Francesca Celletti
Elizabeth Glaser Pediatric AIDS Foundation
Geneva, Switzerland

Natalia Cerqueira
University of São Paulo
São Paulo, Brazil

Jennifer Cohn
Elizabeth Glaser Pediatric AIDS Foundation
Geneva, Switzerland

Demetre Daskalakis
NYC Department of Health and Mental Hygiene
New York, NY, USA

Kevin de Cock
Centers for Disease Control and Prevention
Nairobi, Kenya

Nikos Dedes
Positive Voice
Athens, Greece

Jean-François Delfraissy
Agence Nationale de Recherche sur le Sida et les Hépatites Virales
Paris, France

Mandeepr Dhaliwal
United Nations Development Programme
New York, NY, USA

Lucica Ditiu
Stop TB Partnership
Geneva, Switzerland

Meg Doherty
World Health Organization
Geneva, Switzerland

Mark R. Dybul
Global Fund to Fight AIDS, Tuberculosis, and Malaria
Geneva, Switzerland

Terri Ford
AIDS Healthcare Foundation
Los Angeles, CA, USA

Noel Gill
Public Health England
London, England

Anja Giphart
Elizabeth Glaser Pediatric AIDS Foundation
Washington, DC, USA

Eric Goemaere
Médecins sans Frontières
Cape Town, South Africa

Reuben Granich
International Association of Providers of AIDS Care
Washington, DC, USA

David Haerry
European AIDS Treatment Group
Brussels, Belgium

Catherine Hankins
Amsterdam Institute for Global Health
Amsterdam, Netherlands

Mark Heywood
Section 27
Johannesburg, South Africa

Gottfried Hirnschall
World Health Organization
Geneva, Switzerland

Bernard Hirschel
Geneva University Hospitals
Geneva, Switzerland

Amb. Lennarth Hjelmåker
Ministry of Foreign Affairs
Stockholm, Sweden

Karen Hoover
Centers for Disease Control and Prevention
Atlanta, GA, USA

Andreas Jahn
I-TECH Malawi
Lilongwe, Malawi
CONFERENCE INFORMATION

PROGRAM OVERVIEW
This two-day Controlling the HIV Epidemic with Antiretrovirals summit is hosted by the International Association of Providers of AIDS Care (IAPAC), in collaboration with the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Foundation for AIDS Research (amfAR), the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS), and the Geneva University Hospitals (HUG).

The summit will serve as a forum for the presentation of data related to and discussion about the fast-tracked scale up of HIV treatment and prevention. The summit will also allow clinicians, researchers, public health policy-makers, government officials, donor agency managers, civil society representatives, and other stakeholders to explore ways of generating demand for and increasing access to and utilization of HIV testing, prevention, care, and treatment services, including breaking down structural and other barriers within affected communities.

DISCLOSURE
This year’s summit is made possible through generous sponsorship from Gilead Sciences, Viiv Healthcare, the Foundation for AIDS Research (amfAR), the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), and the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS). IAPAC also acknowledges in-kind support from the Geneva Convention and Visitor’s Bureau.

IAPAC is responsible for control of the summit’s content and faculty selection. In providing their support for the summit, the commercial sponsors agreed that they would have no involvement in the design of the program or the selection of faculty members.

GENERAL INFORMATION

MEETING VENUE
The Controlling the HIV Epidemic with Antiretrovirals summit is being held at the International Conference Centre in Geneva, Switzerland.

MEALS
Coffee breaks will take place as scheduled in the summit program in the conference centre’s Espace Polyvalent near the registration counters. Lunch also will be available on both days in the Espace Polyvalent (buffet style so that delegates may take part in the “Lunch Panel Discussions”).

INTERNET ACCESS
Use these credentials to access the conference centre’s wireless network:

Username: IAPAC
Password: 2016

SLIDE PRESENTATIONS
The summit’s presentations will be posted at www.iapac.org as they are delivered.

SOCIAL MEDIA
IAPAC encourages you to use social media to communicate your thoughts about the summit proceedings. The summit’s Twitter hashtag is #IAPAC2016.

QUESTIONS
If you have any questions during the summit, please locate an IAPAC staff member in the Registration Area. If you have any questions post-summit, please contact Jonathon Hess, IAPAC’s Conference Manager, at jhess@iapac.org.
Join us as we commemorate our 30th anniversary; recognize 150 friends and colleagues; and honor Ambassador Deborah L. Birx, MD, with our 2016 Jonathan Mann Health Human Rights Award.

Thursday, October 13, 2016
~ 6:00 PM – 8:00 PM ~
Geneva International Conference Centre
Espace Polyvalent
Controlling the HIV Epidemic with Antiretrovirals: Leveraging Progress, Seizing Opportunities is hosted by the International Association of Providers of AIDS Care (IAPAC), in partnership with the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Foundation for AIDS Research (amfAR), the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS), and the Geneva University Hospitals (HUG). We wish to express our gratitude to the institutional and commercial sponsors whose generosity has made our 2016 summit possible.

Institutional Supporters

<table>
<thead>
<tr>
<th>IAPAC</th>
<th>UNAIDS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>amfAR</th>
<th>Elizabeth Glaser Pediatric AIDS Foundation</th>
<th>ANRS</th>
<th>HUG</th>
</tr>
</thead>
</table>

Commercial Supporters

<table>
<thead>
<tr>
<th>Gilead Healthcare</th>
</tr>
</thead>
</table>

www.IAPAC.org